Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Long-Term Investments (2017 - 2025)

Aclaris Therapeutics (ACRS) has 6 years of Long-Term Investments data on record, last reported at $60.6 million in Q4 2025.

  • For Q4 2025, Long-Term Investments fell 32.88% year-over-year to $60.6 million; the TTM value through Dec 2025 reached $60.6 million, down 32.88%, while the annual FY2025 figure was $60.6 million, 32.88% down from the prior year.
  • Long-Term Investments reached $60.6 million in Q4 2025 per ACRS's latest filing, down from $71.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $91.0 million in Q2 2023 and bottomed at $7.2 million in Q2 2022.
  • Average Long-Term Investments over 5 years is $50.0 million, with a median of $45.7 million recorded in 2024.
  • Peak YoY movement for Long-Term Investments: tumbled 79.07% in 2022, then skyrocketed 1160.1% in 2023.
  • A 5-year view of Long-Term Investments shows it stood at $34.2 million in 2021, then crashed by 64.25% to $12.2 million in 2022, then soared by 412.75% to $62.8 million in 2023, then soared by 43.86% to $90.3 million in 2024, then tumbled by 32.88% to $60.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $60.6 million in Q4 2025, $71.3 million in Q3 2025, and $81.1 million in Q2 2025.